{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:18:54Z","timestamp":1791425934933,"version":"4.3.3"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T00:00:00Z","timestamp":1292889600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0000923","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T14:02:31Z","timestamp":1292940151000},"page":"e923","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":276,"title":["Fexinidazole \u2013 A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness"],"prefix":"10.1371","volume":"4","author":[{"given":"Els","family":"Torreele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Bourdin Trunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tweats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Mazu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"P\u00e9coul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,12,21]]},"reference":[{"key":"ref1","first-page":"553","article-title":"The impact of diversity-based, high-throughput screening on drug discovery: \u201cchance favours the prepared mind\u201d.","volume":"11","author":"M Snowden","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref2","article-title":"HTS and hit finding in academia\u2013from chemical genomics to drug discovery. Drug Discov Today 14: 1150-1158.","volume":"28","author":"JA Frearson","year":"2009","journal-title":"Epub 2009 Sep"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1126\/science.1095920","article-title":"Protein kinase inhibitors: insights into drug design from structure.","volume":"303","author":"ME Noble","year":"2004","journal-title":"Science"},{"key":"ref4","article-title":"WHO fact sheet.","volume":"28"},{"key":"ref5","first-page":"71","article-title":"Human African trypanosomiasis (sleeping sickness): epidemiological update.","volume":"8","author":"WHO","year":"2006","journal-title":"Weekly Epidemiological Record"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1371\/journal.pmed.0050055","article-title":"Eliminating human African trypanosomiasis: where do we stand and what comes next?","volume":"5","author":"PP Simarro","year":"2008","journal-title":"PLoS Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis.","volume":"375","author":"R Brun","year":"2010","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0707354","article-title":"Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.","volume":"152","author":"MP Barrett","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1172\/JCI200421052","article-title":"Human African trypanosomiasis of the CNS: current issues and challenges.","volume":"113","author":"PG Kennedy","year":"2004","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1473-3099(02)00321-3","article-title":"Treatment of human African trypanosomiasis: present situation and needs for research and development.","volume":"2","author":"D Legros","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1406.071266","article-title":"High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo.","volume":"14","author":"J Robays","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-3156.2001.00712.x","article-title":"Melarsoprol refractory T. b. gambiense from Omugo, northwestern Uganda.","volume":"6","author":"E Matovu","year":"2001","journal-title":"Trop Med Int Health"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1086\/432576","article-title":"Eflornithine is safer than melarsoprol for the treatment of second-stage <italic>Trypanosoma brucei gambiense<\/italic> human African trypanosomiasis.","volume":"41","author":"F Chappuis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African <italic>Trypanosoma brucei gambiense<\/italic> trypanosomiasis: a multicentre, randomised phase III, non-inferiority trial.","volume":"374","author":"G Priotto","year":"2009","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(09)61163-6","article-title":"NECT trial: more than a small victory over sleeping sickness.","volume":"374","author":"J Opigo","year":"2009","journal-title":"Lancet"},{"key":"ref16"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3201\/eid1602.090967","article-title":"Human African trypanosomiasis in areas without surveillance.","volume":"16","author":"F Chappuis","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"ref18","article-title":"Chemotherapeutically active nitro compounds. 4. 5-Nitroimidazoles (Part I-IV).","volume":"27-28","author":"E Winkelmann","year":"1977","journal-title":"Arzneimittelforschung"},{"key":"ref19","first-page":"347","article-title":"An efficacy trial on <italic>Trypanosoma brucei brucei<\/italic> of molecules permeating the blood-brain barrier and of megazol.","volume":"87","author":"A Marie-Daragon","year":"1994","journal-title":"Bull Soc Pathol Exot"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0001-706X(95)00109-R","article-title":"Effect of megazol on <italic>Trypanosoma brucei brucei<\/italic> acute and subacute infections in Swiss mice.","volume":"60","author":"B Bouteille","year":"1995","journal-title":"Acta Trop"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.mrgentox.2004.02.013","article-title":"<italic>In vitro<\/italic> and <italic>in vivo<\/italic> chromosomal aberrations induced by megazol.","volume":"560","author":"F Nesslany","year":"2004","journal-title":"Mutat Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1128\/AAC.47.10.3368-3370.2003","article-title":"Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage.","volume":"47","author":"B Enanga","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/em.2850190212","article-title":"Evaluation of the mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivatives by the Ames test and the SOS chromotest.","volume":"19","author":"M De Meo","year":"1992","journal-title":"Environ Mol Mutagen"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0165-1110(81)90006-3","article-title":"On the mutagenicity of nitroimidazoles.","volume":"86","author":"CE Voogd","year":"1981","journal-title":"Mutat Res"},{"key":"ref25","first-page":"679","article-title":"Metronidazole. A therapeutic review and update.","volume":"54","author":"CD Freeman","year":"1997","journal-title":"Drugs"},{"key":"ref26","first-page":"969","article-title":"New chemotherapeutically active nitroimidazoles.","volume":"11th 2","author":"E Winkelmann","year":"1980","journal-title":"Curr Chemother Infect Dis, Proc Int Congr Chemother"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/00034983.1983.11811668","article-title":"The activity of fexinidazole (HOE 239) against experimental infections with <italic>Trypanosoma cruzi<\/italic>, trichomonads and <italic>Entamoeba histolytica<\/italic>.","volume":"77","author":"W Raether","year":"1983","journal-title":"Ann Trop Med Parasitol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF00926669","article-title":"The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic <italic>T. brucei<\/italic> infections in mice.","volume":"69","author":"FW Jennings","year":"1983","journal-title":"Z Parasitenkd"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0001-706X(97)00079-X","article-title":"The Alamar Blue assay to determine drug sensitivity of African trypanosomes in vitro.","volume":"68","author":"B R\u00e4z","year":"1997","journal-title":"Acta Trop"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/j.1460-2075.1985.tb03772.x","article-title":"Cultivation in a semi-defined medium of animal infective forms of <italic>Trypanosoma brucei<\/italic>, <italic>T. equiperdum<\/italic>, <italic>T. evansi<\/italic>, <italic>T. rhodesiense<\/italic> and <italic>T. gambiense<\/italic>.","volume":"4","author":"T Baltz","year":"1985","journal-title":"EMBO J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/AAC.00225-09","article-title":"New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.","volume":"53","author":"T Wenzler","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/AAC.42.11.2858","article-title":"<italic>In Vitro<\/italic> and <italic>In Vivo<\/italic> Activities of Trybizine Hydrochloride against Various Pathogenic Trypanosome Species. Antimicrob.","volume":"42","author":"R Kaminsky","year":"1998","journal-title":"Agents and Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.actatropica.2008.07.006","article-title":"Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis.","volume":"108","author":"JK Thuita","year":"2008","journal-title":"Acta Trop"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and <italic>in vitro<\/italic> metabolism data.","volume":"283","author":"RS Obach","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"ref35","first-page":"23","article-title":"A Method for the Simultaneous Evaluation of the Activities of Seven Major Human Drug-Metabolizing Cytochrome P450s Using an in Vitro Cocktail of Probe Substrates and Fast Gradient Liquid Chromatography Tandem Mass Spectrometry.","volume":"29","author":"EA Dierks","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1021\/bp050208u","article-title":"Role of Caco-2 cell monolayers in prediction of intestinal drug absorption,","volume":"22","author":"P Shah","year":"2006","journal-title":"Biotechnol Prog"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijpharm.2004.10.007","article-title":"Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.","volume":"288","author":"Q Wang","year":"2005","journal-title":"Int J Pharm"},{"key":"ref38","article-title":"ICH Topic S 7 A. \u201cSafety Pharmacology Studies for Human Pharmaceuticals\u201d.","year":"2001"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/bjp.2008.280","article-title":"Principles of safety pharmacology.","volume":"154","author":"MK Pugsley","year":"2008","journal-title":"Br J Pharmacol"},{"key":"ref40","article-title":"ICH Topic S 7 B. \u201cThe nonclinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals\u201d.","year":"2005"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF00401402","article-title":"Comprehensive observational assessment: 1a. A systematic, quantitative procedure for assessing the behavioural and physiologic state of the mouse.","volume":"13","author":"S Irwin","year":"1968","journal-title":"Psychopharmacologia (Berl)"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ddr.430320408","article-title":"Safety Pharmacology of the Respiratory System: Techniques and Study Design.","volume":"32","author":"DJ Murphy","year":"1994","journal-title":"Drug Dev Res"},{"key":"ref43","article-title":"ICH Topic M 3 (R2). \u201cNon-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals\u201d","year":"2009"},{"key":"ref44","article-title":"ICH Topic S 3 A. \u201cToxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies\u201d.","year":"1995"},{"key":"ref45","article-title":"ICH Topic S 5A Reproductive toxicology: detection of toxicity to reproduction for medicinal products including toxicity to male fertility (CPMP\/ICH\/386\/95).","year":"1994"},{"key":"ref46","article-title":"ICH Topic S2 (R1). Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use.","year":"2008"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/em.2860030403","article-title":"Evidence for the existence of a family of bacterial nitroreductases capable of activating nitrated polycyclics to mutagens.","volume":"3","author":"EC McCoy","year":"1981","journal-title":"Environ Mutagen"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/tx000002x","article-title":"Mutagenicity of nitroaromatic compounds.","volume":"13","author":"V Purohit","year":"2000","journal-title":"Chem Res Toxicol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0165-1161(83)90010-9","article-title":"Revised methods for the Salmonella mutagenicity test.","volume":"113","author":"DM Maron","year":"1983","journal-title":"Mutat Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nprot.2007.77","article-title":"Cytokinesis-block micronucleus cytome assay.","volume":"2","author":"M Fenech","year":"2007","journal-title":"Nature Protocols"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0027-5107(00)00117-2","article-title":"<italic>In vivo<\/italic> micronucleus assay: protocol, conduct and interpretation.","volume":"455","author":"G Krishna","year":"2000","journal-title":"Mutat Res"},{"key":"ref52","article-title":"<italic>In<\/italic> v<italic>ivo<\/italic> rat liver UDS assay. In: Supplementary Mutagenicity Tests UKEMS Recommended Procedures. Kirkland DJ, Fox M editors. Cambridge: Cambridge University Press.","volume":"52-77","author":"JC Kennelly","year":"1993","journal-title":"pp"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1063\/1.555843","article-title":"Reduction potentials of one-electron couples involving free radicals in aqueous solution.","volume":"18","author":"P Wardman","year":"1989","journal-title":"J Phys Chem Ref Data"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.2174\/1381612043383214","article-title":"Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis.","volume":"10","author":"CE Barry III","year":"2004","journal-title":"Curr Pharm Des"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benzidazole in trypanosomes,","volume":"105","author":"SR Wilkinson","year":"2008","journal-title":"Proc Nat Acad Sci USA"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited.","volume":"22","author":"S Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/mutage\/gem006","article-title":"<italic>In vitro<\/italic> approaches to develop weight of evidence (W0E) and mode of action (MoA) discussions with positive in vitro genotoxicity results.","volume":"22","author":"DJ Kirkland","year":"2007","journal-title":"Mutagenesis"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1383-5718(02)00105-5","article-title":"Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound.","volume":"518","author":"W Suter","year":"2002","journal-title":"Mutat Res"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.","volume":"405","author":"CK Stover","year":"2000","journal-title":"Nature"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.","volume":"3","author":"M Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10590500902885593","article-title":"Predictive models for carcinogenicity and mutagenicity frameworks, state-of-the-art and perspectives.","volume":"27","author":"E Benfenati","year":"2009","journal-title":"J Environ Sci Health C Eviron Carcinog Ecotoxicol Rev"},{"key":"ref62"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0000923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T19:32:53Z","timestamp":1740771173000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0000923"}},"subtitle":[],"editor":[{"given":"Marleen","family":"Boelaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,21]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0000923","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,21]]}}}